';

STI Panel Test

Preventing the spread of sexually transmitted infections

QMDx_Q-POC_STI00

Providing diagnostic and drug sensitivity testing in less than 20 minutes will enable patients to immediately receive the treatment they need.

The Problem

Current screening initiatives for these often symptomless infections are hindered by long turnaround times, with many patients never returning for treatment.

450,000 new STI cases in the UK each year
820,000 new cases of gonorrhoea alone in the USA each year
246,000 out of the 820,000 gonorrhoea cases are drug resistant
STDs cost the U.S. health care system $17 billion every year
Testing for the two most common sexually transmitted infections chlamydia trachomatis (chlamydia) and neisseria gonorrhea (gonorrhea) currently relies upon culture, which takes at least 48 hours. Unfortunately the stigma associated with these diseases prevent many from returning to clinics for treatment.

Sexually transmitted diseases (STDs) can be caused by infections that are passed from one person to another through sexual contact. It can also be transmitted through nonsexual modes such as from mother-to-infant during pregnancy, childbirth, blood transfusions, and through shared needles. In addition, people can pass STDs to their sexual partners without any symptoms to themselves. This can result in a lack of care seeking and appropriate treatment.

Current STI testing in an outpatient setting (often in genito-urinary clinics) relies on lab culture to identify infections and any drug resistance. This takes at least 48 hours. In the meantime, the patient is prescribed a first line antibiotic treatment.

However, increasingly the pathogens are resistant to these treatments. Therefore in a growing proportion of cases, the primary treatment will be ineffective and the patient will be recalled to receive a follow up consultation. This is where the treatment of STIs is significantly complicated by social stigma, economic, and behavioural factors.

Untreated or inappropriately treated STDs can lead to a range of secondary complications including pelvic inflammatory disease, infertility, complications in pregnancy (ectopic pregnancy or transmission of infection to a foetus), reproductive system cancers, enhanced transmission of HIV and epididymitis; each with a cost to the healthcare system. The emergence of drug resistant strains of STI such as gonorrhea is also causing considerable global concern.

Partnerships

Global Partnerships, Global Vision

Access to samples, clinical development and trial partners.
Partnerships

Global Partnerships, Global Vision

Access to samples, clinical development and trial partners.
The Solution

Enabling gold-standard molecular diagnostic testing and treatment in a single patient consultation.

This important panel test will harness the power of molecular diagnostics to support crucial screening programmes for the most common sexually transmitted infections.

QuantuMDx is developing an STI panel test to provide accurate and reliable testing at the patient’s side. By providing results in minutes, this test will enable immediate prescription of the most effective drug treatment. As well as treating the individual and preventing secondary complications, this rapid testing will help to prevent further spread of the infections within the community.

We are working within the UK-based eSTI2 (electronic sexually transmitted infections) consortium to access expertise in the field, ensuring our assay meets the needs of clinicians and fits seamlessly within their care pathways.

We are working as part of the eSTI2 consortium.

esti2_LOGO

We are working as part of the eSTI2 consortium.

esti2_LOGO

Subscribe to our e-newsletter and keep up to date with QuantuMDx

THE FUTURE OF DIAGNOSTICS

Tackling drug resistance
To preserve antibiotics for future generations

Antimicrobial resistance threatens the effectiveness of our most important pharmaceuticals, leaving our communities defenseless against many common infections.

Supporting health research
To improve healthcare provision globally

Our Internet of Life™ will enable reporting of real-time genomic pathogen data, increasing our collective knowledge and informing drug development.

Tackling drug resistance
To preserve antibiotics for future generations

Antimicrobial resistance threatens the effectiveness of our most important pharmaceuticals, leaving our communities defenseless against many common infections.

Supporting health research
To improve healthcare provision globally

Our Internet of Life™ will enable reporting of real-time genomic pathogen data, increasing our collective knowledge and informing drug development.

  • DNA-XT™
    Sample Preparation

    Our next generation spin column will purify high-quality DNA for PCR, sequencing and other molecular processes.

  • Diagnostics
    Under the Tree

    Supporting disease eradication efforts with simple and accurate diagnostic testing in the community.

  • Q-POC™
    Handheld Diagnostics

    Our handheld, battery-operated molecular diagnostic device will provide sample-to-result testing in less than 20 minutes.

  • Internet of Life™
    Networking Disease Data

    Globally distributed Q-POC devices will geotag and anonymise pathogen data, and send it to the cloud for real-time disease and drug resistance monitoring.

Contact

Contact

Contact